News
-
Pre-announcement – EP PerMed Joint Transnational Call (JTC) 2027
EP PerMed is launching the Joint Transnational Call 2027 ‘Cell and Gene Therapy for Personalised Medicine’ (CGT4PM2027). The call aims to fund projects focusing on the development and validation of innovative and novel cell and gene therapies for personalised medicine. The full call text is expected to be published on 4 November 2026.
-
JA PCM Invites Stakeholders to Shape a Public-Private Partnership for Personalised Cancer Medicine
The Joint Action on Personalised Cancer Medicine (JA PCM) is inviting patients, citizens and public stakeholders to two online consultations on 26 and 27 October 2026. The discussions will contribute to the development of a possible public-private partnership (PPP) for personalised cancer medicine that could continue beyond the Joint Action.
-
Commission Webinar on Pre-Commercial Procurement for Health and Cancer
The European Commission will host an information webinar on 12 October 2026 on pre-commercial procurement (PCP) in Horizon Europe. Organised by the Commission’s Health Innovation and Ecosystems Unit and the EU Cancer Mission, the session will present two 2027 funding topics: Cancer technologies, medical devices and medicines and Health adaptation to climate change.
-
EP PerMed CONNECT: Innovation Meets Implementation
From 30 September to 01 October 2026, EP PerMed will host an event focusing on reverse tech transfer entitled EP PerMed CONNECT: Innovation Meets Implementation. Limited seats are available.
EP PerMed JTC2027
Cell and Gene Therapy for Personalised Medicine (CGT4PM2027)
The EP PerMed Joint Transnational Call 2027 ‘Cell and Gene Therapy for Personalised Medicine’ (CGT4PM2027) aims to fund projects focusing on the development and validation of innovative and novel cell and gene therapies for personalised medicine.
Citizen Awareness of Personalised Medicine
Your opinion matters!
Have you been involved in a personalised treatment or are you aware of personalised medicine approaches?
EP PerMed likes to understand how well people are informed about personalised medicine, how they perceive it, and their thoughts on its potential benefits and challenges.
The anonymous survey contains 36 questions and takes approximately 10-15 minutes to complete. It is currently available in: English, Czech, Danish, Finnish, French, German, Greek, Italian, Norwegian, Dutch, Polish, Portuguese, Romanian, Spanish, Swedish and Turkish.
Mission & Objectives
EP PerMed Podcast ‘The Science of You’
The second season of the EP PerMed podcast tells four powerful stories of patients and former patients who have benefited from personalised medicine. With topics ranging from oncology and rare genetic disorders to preventive surgery and cardiovascular diseases, this season illustrates real human experiences, showing how tailored therapies are transforming the treatment process into a more effective and informed one.